Quality of life outcomes in peri-urethral calcium hydroxylapatite injection

Griffin, Michael; Janosek-Albright, Kirsten; Diaz-Insua, Mireya; Elshatanoufy, Solafa; Atiemo, Humphrey

doi:10.1007/s00192-016-3053-1

Cited by 2 publications

(9 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A total of 583 articles were screened using the search criteria to assess for eligibility. Final number of studies included was 17 for Bulkamid®, [12][13][14][16][17][18][19][20][21][22][23][24][25][26][27][28][29] 23 for Macro-plastique®, 6,7, 5 for Durasphere®, 8,9,[51][52][53] 5 for Coap-tite®, 11,[54][55][56][57] and 6 for Urolastic® 15,[58][59][60][61][62] (Figure 1). Risk of bias assessment can be found in Table S1.…”

Section: Resultsmentioning

confidence: 99%

“…Five studies were included 11,54–57 . The number of participants in each study ranged from 10 to 131, with 266 patients altogether.…”

Section: Resultsmentioning

confidence: 99%

Section: Reinjection Ratesmentioning

confidence: 96%

“…Four studies reported a reinjection rate of 15.6% to 70%, [54][55][56][57] with no significant difference between Coap-tite® and Contigen®. 57 3.4.4 | Adverse events AUR was reported by 3 studies to range from 11.7% to 50%, 54,56,57 UTI rates ranged from 0% to 30% as reported by 3 studies. 54,56,57 De novo urgency was reported in 2 studies ranging from 0% to 5.7%, 56,57 and was significantly less frequent in Coaptite® patients compared to Contigen®.…”

Section: Reinjection Ratesmentioning

confidence: 96%

“…57 3.4.4 | Adverse events AUR was reported by 3 studies to range from 11.7% to 50%, 54,56,57 UTI rates ranged from 0% to 30% as reported by 3 studies. 54,56,57 De novo urgency was reported in 2 studies ranging from 0% to 5.7%, 56,57 and was significantly less frequent in Coaptite® patients compared to Contigen®. 56 Two serious adverse events were reported.…”

Section: Reinjection Ratesmentioning

confidence: 99%

See 4 more Smart Citations

Urethral bulking agents for the treatment of stress urinary incontinence in women: A systematic review

Hoe

Haller

Yao

et al. 2021

Neurourology and Urodynamics

View full text Add to dashboard Cite

Aims: To perform a systematic review to assess and compare the efficacy and safety of all urethral bulking agents (UBAs) available for the treatment of stress urinary incontinence (SUI) in women.Methods: This systematic review was conducted in accordance with the PRISMA guideline. A systematic search was conducted using the Ovid Medline, Embase and PubMed databases. Studies were included if they involved women who underwent either Bulkamid®, Macroplastique®, Durasphere®, Coaptite®, or Urolastic® injections for the treatment of SUI. A total of 583 articles were screened with 56 articles included. A qualitative analysis was performed.Results: The newer synthetic UBAs are not inferior to Contigen®, with variable mean success rates of 30%-80% in the short-term. Better long-term success rates were found with Bulkamid® (42%-70%), Coaptite® (60%-75%), and Macroplastique® (21%-80%) on qualitative review. Urinary tract infection rates were similar between bulking agents (4%-10.6%) although temporary acute urinary retention was more commonly associated with Coaptite® (mean: 34.2%), and de novo urgency in Durasphere® (mean: 24.7%). Significant complications such as migration into lymph nodes was reported with Dura-sphere®. Erosion was reported with Macroplastique®, Coaptite®, and Urolastic®, with a rate as high as 24.6% in one study of Urolastic®. Conclusion: Available data support the use of Bulkamid® and Macro-plastique®, which has shown a short-term efficacy of 30%-90% and 40%-85% respectively, and long-term efficacy of 42%-70%, and 21%-80%, respectively. Bulkamid® appears to have a more favorable safety profile, with no cases of erosion or migration of product associated with its use. Direct comparisons of UBAs have not been performed.

show abstract

Section: Resultsmentioning

confidence: 99%

“…Five studies were included 11,54–57 . The number of participants in each study ranged from 10 to 131, with 266 patients altogether.…”

Section: Resultsmentioning

confidence: 99%

Section: Reinjection Ratesmentioning

confidence: 96%

Section: Reinjection Ratesmentioning

confidence: 96%

Section: Reinjection Ratesmentioning

confidence: 99%

See 3 more Smart Citations

Urethral bulking agents for the treatment of stress urinary incontinence in women: A systematic review

Hoe

Haller

Yao

et al. 2021

Neurourology and Urodynamics

View full text Add to dashboard Cite

show abstract

Animal models, treatment options, and biomaterials for female stress urinary incontinence

Tan,

Li,

et al. 2024

Front. Bioeng. Biotechnol.

View full text Add to dashboard Cite

In the quest to tackle stress urinary incontinence (SUI), the synthesis of cutting-edge biomaterials and regenerative materials has emerged as a promising frontier. Briefly, animal models like vaginal distension and bilateral ovariectomy serve as crucial platforms for unraveling the intricacies of SUI, facilitating the evaluation of innovative treatments. The spotlight, however, shines on the development and application of novel biomaterials—ranging from urethral bulking agents to nano-gel composites—which aim to bolster urethral support and foster tissue regeneration. Furthermore, the exploration of stem cell therapies, particularly those derived from adipose tissues and urine, heralds a new era of regenerative medicine, offering potential for significant improvements in urinary function. This review encapsulates the progress in biomaterials and regenerative strategies, highlighting their pivotal role in advancing the treatment of SUI, thereby opening new avenues for effective and minimally invasive solutions.

show abstract

Quality of life outcomes in peri-urethral calcium hydroxylapatite injection

Cited by 2 publications

References 15 publications

Urethral bulking agents for the treatment of stress urinary incontinence in women: A systematic review

Urethral bulking agents for the treatment of stress urinary incontinence in women: A systematic review

Animal models, treatment options, and biomaterials for female stress urinary incontinence

Contact Info

Product

Resources

About